• Patients unwilling or unable to discontinue DMARDs for treatment of SSc at time of randomization will be excluded.
• Patients with a history or presence of a 2nd autoimmune disease requiring immunosuppressive thereapy will be excluded

FHCRC 2533 - CBCI-224  

A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation for the Treatment of Systemic Sclerosis

• Patients must have diffuse cutaneous scleroderma with a skin score of ≥16.
• Systemic sclerosis must be ≤ 7 years from the onset of first non-Raynaud's symtoms.
• Patient must have presence of
  interstitial lung disease or left heart failure or histoyr of renal
  disease that is not active at the time of screening

FHCRC 2067 - CBCI-237

Allogeneic Hematopoietic Cell Transplantation after Neonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis

Criteria to qualify for study:

Drug used in study:

• Patients must have failed at least 2
  lines of standard therapy.
• Pateints with evidence of myelodysplasia will be excluded

FHCRC 2260 CBCI-232

High-Dose Immunosouppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients with Autoimmune Neurologic Disease